JP2009102341A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009102341A5 JP2009102341A5 JP2008309431A JP2008309431A JP2009102341A5 JP 2009102341 A5 JP2009102341 A5 JP 2009102341A5 JP 2008309431 A JP2008309431 A JP 2008309431A JP 2008309431 A JP2008309431 A JP 2008309431A JP 2009102341 A5 JP2009102341 A5 JP 2009102341A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- rapamycin
- hydroxy
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 239000003826 tablet Substances 0.000 claims 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 3
- 229960002930 sirolimus Drugs 0.000 claims 3
- 239000007962 solid dispersion Substances 0.000 claims 3
- 239000007884 disintegrant Substances 0.000 claims 2
- 239000007919 dispersible tablet Substances 0.000 claims 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0123400.4A GB0123400D0 (en) | 2001-09-28 | 2001-09-28 | Organic compounds |
| GB0123400.4 | 2001-09-28 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003532038A Division JP2005507897A (ja) | 2001-09-28 | 2002-09-27 | コロイド状二酸化ケイ素を含んでなる医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009102341A JP2009102341A (ja) | 2009-05-14 |
| JP2009102341A5 true JP2009102341A5 (https=) | 2011-12-08 |
| JP5160386B2 JP5160386B2 (ja) | 2013-03-13 |
Family
ID=9922916
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003532038A Withdrawn JP2005507897A (ja) | 2001-09-28 | 2002-09-27 | コロイド状二酸化ケイ素を含んでなる医薬組成物 |
| JP2008309431A Expired - Lifetime JP5160386B2 (ja) | 2001-09-28 | 2008-12-04 | コロイド状二酸化ケイ素を含んでなる医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003532038A Withdrawn JP2005507897A (ja) | 2001-09-28 | 2002-09-27 | コロイド状二酸化ケイ素を含んでなる医薬組成物 |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US20040254210A1 (https=) |
| EP (2) | EP1432408B8 (https=) |
| JP (2) | JP2005507897A (https=) |
| KR (1) | KR100626785B1 (https=) |
| CN (3) | CN1951390B (https=) |
| AR (2) | AR036643A1 (https=) |
| AT (1) | ATE485813T1 (https=) |
| BR (2) | BRPI0212922B1 (https=) |
| CA (1) | CA2458455C (https=) |
| CO (1) | CO5390072A1 (https=) |
| CY (2) | CY1111119T1 (https=) |
| DE (1) | DE60238131D1 (https=) |
| DK (2) | DK1432408T3 (https=) |
| EC (1) | ECSP024323A (https=) |
| ES (2) | ES2560106T3 (https=) |
| GB (1) | GB0123400D0 (https=) |
| HU (1) | HU229991B1 (https=) |
| IL (2) | IL160498A0 (https=) |
| MX (1) | MXPA04002814A (https=) |
| MY (1) | MY150060A (https=) |
| NO (1) | NO333892B1 (https=) |
| NZ (2) | NZ542273A (https=) |
| PE (1) | PE20030602A1 (https=) |
| PL (1) | PL209704B1 (https=) |
| PT (2) | PT2193788E (https=) |
| RU (1) | RU2322970C2 (https=) |
| SI (1) | SI1432408T1 (https=) |
| TW (1) | TWI242449B (https=) |
| WO (1) | WO2003028705A1 (https=) |
| ZA (1) | ZA200401300B (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| JP4547911B2 (ja) | 2002-02-01 | 2010-09-22 | アリアド・ファーマシューティカルズ・インコーポレイテッド | リン含有化合物およびその用途 |
| DE60324609D1 (de) * | 2002-09-17 | 2008-12-18 | Wyeth Corp | GRANULIERTE FORMULIERUNG DES RAPAMYCINESTERS CCl-779 |
| EP1568381A1 (en) * | 2002-10-09 | 2005-08-31 | Kyowa Hakko Kogyo Co., Ltd. | Remedy for hormone-dependent cancer |
| DE10351448A1 (de) * | 2003-11-04 | 2005-06-09 | Bayer Healthcare Ag | Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften |
| JP5427409B2 (ja) * | 2005-06-09 | 2014-02-26 | ハンサ メディカル アクチボラゲット | 自己免疫疾患及び移植片拒絶反応を治療するためのＩｄｅＳプロテイナーゼ（化膿連鎖球菌由来）の使用 |
| CN103330694A (zh) * | 2006-11-14 | 2013-10-02 | 阿里亚德医药股份有限公司 | 口服制剂 |
| PL3150586T3 (pl) | 2007-02-23 | 2020-06-01 | Gilead Sciences, Inc. | Modulatory farmakokinetycznych właściwości środków terapeutycznych |
| HRP20151357T1 (hr) | 2008-05-02 | 2016-01-29 | Gilead Sciences, Inc. | Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa |
| CN101444494B (zh) * | 2008-12-31 | 2011-03-30 | 江苏大学 | 难溶性药物高效长效缓释制剂及其制法 |
| CN101444503B (zh) * | 2008-12-31 | 2011-02-02 | 江苏大学 | 一种水飞蓟宾高效长效制剂及其制法 |
| CN101439025B (zh) * | 2008-12-31 | 2011-05-11 | 江苏大学 | 一种水飞蓟素高效长效制剂及其制法 |
| PT2389070E (pt) * | 2009-01-21 | 2013-10-21 | Mylan Inc | Formulações desintegráveis de carbonato de lantânio |
| US8728516B2 (en) | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
| TWI532484B (zh) * | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
| TWI540132B (zh) * | 2009-06-08 | 2016-07-01 | 亞培公司 | Ｂｃｌ-２族群抑制劑之口服醫藥劑型 |
| SG10201500152UA (en) | 2009-12-22 | 2015-03-30 | Abbvie Inc | Abt-263 capsule |
| US20170087134A1 (en) * | 2010-07-12 | 2017-03-30 | Salix Pharmaceuticals, Ltd | Formulations of rifaximin and uses thereof |
| US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
| US20120045433A1 (en) * | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
| CA3152557A1 (en) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| TWI620736B (zh) | 2010-11-23 | 2018-04-11 | 艾伯維巴哈馬有限公司 | 使用選擇性ｂｃｌ-２抑制劑之治療方法 |
| PT2643322T (pt) | 2010-11-23 | 2017-11-13 | Abbvie Inc | Sais e formas cristalinas de um agente indutor de apoptose |
| US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
| DE102011052396A1 (de) * | 2011-08-04 | 2013-02-07 | Gelita Ag | Verfahren zur Herstellung einer stabilen Dispersion von Nanopartikeln, hergestellte Dispersion und deren Verwendung |
| KR101151890B1 (ko) * | 2011-08-11 | 2012-05-31 | 동아제약주식회사 | 안정화 및 가용화된 시롤리무스 유도체 조성물의 제조방법 |
| JP6368242B2 (ja) | 2011-10-06 | 2018-08-01 | ノバルティス アーゲー | ４０−ｏ−（２−ヒドロキシ）エチル−ラパマイシンを含む医薬組成物 |
| CN102793673A (zh) * | 2012-09-07 | 2012-11-28 | 中国药科大学 | 一种小檗碱磷脂复合物固体分散体及其制备方法 |
| WO2014117035A1 (en) | 2013-01-24 | 2014-07-31 | Transderm, Inc. | COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TW201503912A (zh) | 2013-03-19 | 2015-02-01 | Novartis Ag | 包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物 |
| CN105899232A (zh) | 2013-11-13 | 2016-08-24 | 诺华股份有限公司 | 用于增强免疫应答的mTOR抑制剂 |
| CN103610646B (zh) * | 2013-12-05 | 2015-07-15 | 江苏奥赛康药业股份有限公司 | 一种含依维莫司的组合物及其制备方法和含有这一组合物的药物制剂 |
| US10287354B2 (en) | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
| WO2016014530A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| WO2016135740A1 (en) | 2015-02-23 | 2016-09-01 | Natco Pharma Limited | Process for preparing stable oral compositions of everolimus |
| HK1245095A1 (zh) | 2015-05-20 | 2018-08-24 | Novartis Ag | 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合 |
| US10383860B2 (en) | 2015-07-28 | 2019-08-20 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical composition comprising rapamycin or derivative thereof, and method for producing the same |
| JP6855470B2 (ja) * | 2016-05-27 | 2021-04-07 | 日本化薬株式会社 | ラパマイシン又はその誘導体を含有する医薬組成物 |
| PT3518924T (pt) | 2016-09-30 | 2022-10-27 | Salix Pharmaceuticals Inc | Formas de dispersão sólidas de rifaximina |
| CN110114070A (zh) | 2016-11-23 | 2019-08-09 | 诺华公司 | 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法 |
| JP7108631B2 (ja) | 2017-01-06 | 2022-07-28 | パルヴェラ セラピューティクス、インク． | ｍＴＯＲ阻害剤の無水組成物およびその使用方法 |
| CN110831582B (zh) | 2017-07-05 | 2023-08-11 | 诺华股份有限公司 | 药物组合物 |
| CN108125918B (zh) * | 2018-01-12 | 2020-06-23 | 杭州中美华东制药有限公司 | 依维莫司药物组合物 |
| US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
| US11000513B2 (en) | 2018-07-02 | 2021-05-11 | Palvella Therapeutics, Inc. | Anhydrous compositions of mTOR inhibitors and methods of use |
| CN115666516A (zh) * | 2020-06-01 | 2023-01-31 | 希尔帕医疗保健有限公司 | 包括卡培他滨的快速分散药物组合物 |
| WO2022219652A1 (en) * | 2021-04-17 | 2022-10-20 | Bdr Pharmaceuticals International Private Limited | Novel sublingual pharmaceutical formulations for everolimus |
| CN119523923A (zh) * | 2024-11-21 | 2025-02-28 | 华中药业股份有限公司 | 一种左炔诺孕酮片及其制备方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8608080D0 (en) | 1986-04-02 | 1986-05-08 | Fujisawa Pharmaceutical Co | Solid dispersion composition |
| US5211958A (en) * | 1987-11-30 | 1993-05-18 | Gist-Brocades, N.V. | Pharmaceutical composition and process for its preparation |
| US4920102A (en) | 1988-04-18 | 1990-04-24 | Eli Lilly And Company | Method for treating gastrointestinal disorders |
| IT1246383B (it) * | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per il mascheramento del sapore di farmaci |
| SK281920B6 (sk) | 1991-07-03 | 2001-09-11 | Pharmacia And Upjohn Company | Farmaceutická tableta na báze ionexových živíc a spôsob jej výroby |
| US5605889A (en) | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
| PE52896A1 (es) | 1994-10-26 | 1996-12-12 | Novartis Ag | Composicion farmaceutica |
| BE1009856A5 (fr) * | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
| DE19544507B4 (de) | 1995-11-29 | 2007-11-15 | Novartis Ag | Cyclosporin enthaltende Präparate |
| PT1166651E (pt) * | 1996-02-29 | 2005-04-29 | Fujisawa Pharmaceutical Co | Granulos de desintegracao rapida de um edulcorante sintetico contendo acido silicico e/ou dioxido de silicio |
| JP4064476B2 (ja) | 1996-03-29 | 2008-03-19 | エラワン ファーマスーティカル リサーチ アンドラボラトリー カンパニー リミテッド | 二酸化珪素を有する球状凝集した澱粉 |
| ES2188928T3 (es) * | 1996-04-26 | 2003-07-01 | Shionogi & Co | Pastilla de liberador-rapido s1452. |
| GB2318511A (en) | 1996-10-23 | 1998-04-29 | Eurand Int | Process for the preparation of a pharmaceutical composition for rapid suspension in water |
| CA2271652A1 (en) | 1996-11-12 | 1998-05-22 | Pharmacia & Upjohn Ab | Compact member comprising a plurality of porous cellulose matrices, (pcms), method of manufacturing and use thereof |
| US5989591A (en) | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
| US6080427A (en) * | 1997-04-17 | 2000-06-27 | Bristol-Myers Squibb Company | Cefadroxil monohydrate tablet formulation |
| PT994697E (pt) | 1997-06-13 | 2005-02-28 | Wyeth Corp | Formulacoes de rapamicina para administracao oral |
| DK1064942T3 (da) | 1998-03-26 | 2004-11-01 | Fujisawa Pharmaceutical Co | Sustained release-fremstilling af et makrolid |
| FR2785538B1 (fr) * | 1998-11-06 | 2004-04-09 | Prographarm Laboratoires | Comprime a delitement rapide perfectionne |
| GB9826656D0 (en) * | 1998-12-03 | 1999-01-27 | Novartis Ag | Organic compounds |
| WO2000054752A1 (fr) * | 1999-03-15 | 2000-09-21 | Kaken Pharmaceutical Co., Ltd. | Comprimes a delitement rapide et procede de fabrication |
| FR2793690B1 (fr) | 1999-03-30 | 2003-01-03 | Cll Pharma | Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique |
| AU782005B2 (en) * | 1999-05-21 | 2005-06-30 | Kissei Pharmaceutical Co. Ltd. | Immediate release medicinal compositions for oral use |
| GB0008785D0 (en) | 2000-04-10 | 2000-05-31 | Novartis Ag | Organic compounds |
| CA2311734C (en) * | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
| US20020076437A1 (en) | 2000-04-12 | 2002-06-20 | Sanjeev Kothari | Flashmelt oral dosage formulation |
| GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| JP2008531509A (ja) | 2005-02-25 | 2008-08-14 | エフ．ホフマン−ラ ロシュ アーゲー | 医薬品成分の改良された分散性を有する錠剤 |
| TWI358407B (en) | 2005-06-22 | 2012-02-21 | Lundbeck & Co As H | Crystalline base of escitalopram and orodispersibl |
-
2001
- 2001-09-28 GB GBGB0123400.4A patent/GB0123400D0/en not_active Ceased
-
2002
- 2002-09-26 EC EC2002004323A patent/ECSP024323A/es unknown
- 2002-09-26 AR ARP020103642A patent/AR036643A1/es not_active Application Discontinuation
- 2002-09-26 PE PE2002000948A patent/PE20030602A1/es not_active Application Discontinuation
- 2002-09-27 TW TW091122345A patent/TWI242449B/zh not_active IP Right Cessation
- 2002-09-27 DK DK02774661.9T patent/DK1432408T3/da active
- 2002-09-27 WO PCT/EP2002/010890 patent/WO2003028705A1/en not_active Ceased
- 2002-09-27 DE DE60238131T patent/DE60238131D1/de not_active Expired - Lifetime
- 2002-09-27 SI SI200230928T patent/SI1432408T1/sl unknown
- 2002-09-27 DK DK09177889.4T patent/DK2193788T3/en active
- 2002-09-27 NZ NZ542273A patent/NZ542273A/en not_active IP Right Cessation
- 2002-09-27 IL IL16049802A patent/IL160498A0/xx unknown
- 2002-09-27 PT PT91778894T patent/PT2193788E/pt unknown
- 2002-09-27 MY MYPI20023631A patent/MY150060A/en unknown
- 2002-09-27 BR BRPI0212922-1A patent/BRPI0212922B1/pt unknown
- 2002-09-27 CO CO02087099A patent/CO5390072A1/es not_active Application Discontinuation
- 2002-09-27 CN CN2006101159063A patent/CN1951390B/zh not_active Expired - Lifetime
- 2002-09-27 CN CN2010101174089A patent/CN101912392A/zh active Pending
- 2002-09-27 EP EP02774661A patent/EP1432408B8/en not_active Expired - Lifetime
- 2002-09-27 HU HU0402394A patent/HU229991B1/hu unknown
- 2002-09-27 NZ NZ531599A patent/NZ531599A/en not_active IP Right Cessation
- 2002-09-27 BR BR0212922-1A patent/BR0212922A/pt not_active IP Right Cessation
- 2002-09-27 RU RU2004113205/15A patent/RU2322970C2/ru active
- 2002-09-27 EP EP09177889.4A patent/EP2193788B1/en not_active Expired - Lifetime
- 2002-09-27 AT AT02774661T patent/ATE485813T1/de active
- 2002-09-27 ES ES09177889.4T patent/ES2560106T3/es not_active Expired - Lifetime
- 2002-09-27 PT PT02774661T patent/PT1432408E/pt unknown
- 2002-09-27 ES ES02774661T patent/ES2354687T3/es not_active Expired - Lifetime
- 2002-09-27 CA CA2458455A patent/CA2458455C/en not_active Expired - Lifetime
- 2002-09-27 US US10/490,089 patent/US20040254210A1/en not_active Abandoned
- 2002-09-27 PL PL367896A patent/PL209704B1/pl not_active IP Right Cessation
- 2002-09-27 CN CNA028190459A patent/CN1561201A/zh active Pending
- 2002-09-27 JP JP2003532038A patent/JP2005507897A/ja not_active Withdrawn
- 2002-09-27 MX MXPA04002814A patent/MXPA04002814A/es active IP Right Grant
- 2002-09-27 KR KR1020047004628A patent/KR100626785B1/ko not_active Expired - Lifetime
-
2004
- 2004-02-18 ZA ZA200401300A patent/ZA200401300B/en unknown
- 2004-02-19 IL IL160498A patent/IL160498A/en active IP Right Grant
- 2004-03-26 NO NO20041270A patent/NO333892B1/no not_active IP Right Cessation
-
2008
- 2008-12-04 JP JP2008309431A patent/JP5160386B2/ja not_active Expired - Lifetime
-
2010
- 2010-05-10 US US12/776,711 patent/US20100221331A1/en not_active Abandoned
- 2010-11-30 CY CY20101101091T patent/CY1111119T1/el unknown
-
2011
- 2011-06-13 US US13/158,921 patent/US20110306630A1/en not_active Abandoned
-
2012
- 2012-06-05 US US13/489,396 patent/US8617598B2/en not_active Expired - Fee Related
-
2014
- 2014-08-14 AR ARP140103055A patent/AR097341A2/es unknown
-
2016
- 2016-01-21 CY CY20161100068T patent/CY1117164T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009102341A5 (https=) | ||
| JP2005507897A5 (https=) | ||
| AR097341A2 (es) | Composición farmaceutica que comprende una dispersión de macrólidos sólidos, y un proceso para producir una tableta dispersable que contiene un macrólido | |
| WO2009074351A3 (en) | Solid forms of tenofovir disoproxil | |
| WO2009043844A3 (en) | Orodispersible tablets | |
| MY147641A (en) | Fast release paracetamol tablets | |
| WO2004100857A3 (en) | Highly plastic granules for making fast melting tablets | |
| NZ610729A (en) | Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate | |
| AU2010308458A8 (en) | Orally transformable tablets | |
| WO2006128121A3 (en) | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications | |
| IL192374A0 (en) | Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol | |
| NZ592325A (en) | Extended release oral acetaminophen/tramadol dosage form | |
| JP2009280621A5 (https=) | ||
| NZ610701A (en) | Once daily formulation of lacosamide | |
| TW200621268A (en) | Antimicrobial copolymers and uses thereof | |
| WO2010066749A3 (en) | Ulipristal acetate tablets | |
| WO2011104652A3 (en) | Veterinary compositions | |
| WO2011141791A3 (en) | Extended release formulations of desvenlafaxine base | |
| HRP20100120T1 (hr) | Formulacije s valsartanom | |
| MXPA04005420A (es) | Composicion farmaceutica que comprende un agonista de receptor de 5ht1. | |
| JP2011516544A5 (https=) | ||
| TW200637537A (en) | Pharmaceutical composition containing sibutramine free base and manufacturing method thereof | |
| WO2008092219A3 (en) | Pharmaceutical composition comprising tramadol and ketoprofen | |
| JP2019014666A5 (https=) | ||
| MY145832A (en) | Pharmaceutical composition in the form of a gastric retention tablet containing an active ingredient |